Skip to main content

Table 1 Baseline characteristics SLE + RA (N = 530) stratified by HCQ use

From: Hydroxychloroquine use is not associated with QTc length in a large cohort of SLE and RA patients

Clinical characteristics HCQ (N = 371) NO HCQ (N = 159) p value
Demographics
Female n (%) 329 (89) 136 (87) 0.51
Age (mean ± SD) 46.3(14.1) 55.3 (13.1) < 0.005
Race
White n (%) 83 (23) 57 (37) 0.001
Black n (%) 107 (29) 33 (21) 0.052
Hispanic n (%) 166 (46) 60 (38) 0.13
Other n (%) 8 (2) 6 (3.8) 0.29
Disease characteristics
Disease duration years (mean ± SD) 12.4 (9.03) 11.5 (12.3) 0.43
Immunosuppressant use
Current biologics use n/total (%) 67/238 (28.1) 59/159 (37.1) 0.060
Current steroid use n/total (%) 293/340 (86.2) 61/159 (38.4) < 0.005
CVD risk factors
Hypertension n/total (%) 170/369 (46.1) 76/155 (49) 0.54
Diabetes mellitus n/total (%) 25/368(7) 20/154(13) 0.02
Current smoking n/total (%) 23/371 (6.2) 15/158 (9.5) 0.18
Current statin use n/total (%) 79/244 (32.4) 30/159(18.9) 0.003
Current aspirin use n/total (%) 147/257 (57.2) 31/159(19.5) < 0.005
Ejection fraction% (mean ± SD) 58.1 ± 9.4 62.2 ± 5.1 < 0.005
Ejection fraction ≥ 55% n/total (%) 337/371 (90.8) 150/159 (93.3) 0.18
QTc average (mean ± SD) 434 ± 25.7 441 ± 30.3 0.0079
QTc ≥ 440 n (%) 134/371 (36.1) 86/159 (54.1) < 0.005
QTc ≥ 500 n (%) 13/371 (3.5) 23/159 (14.5) < 0.005
QTc Meds
Any QTc meds n/total (%) 170/368 (46.2) 52/148 (35.1) 0.022
Antidepressants n/total (%) 61/173 (35.3) 32/44 (72.7) < 0.005
Antipsychotics n/total (%) 15/150 (10) 4/18 (22.2) 0.13
Antiarrhythmics n/total (%) 3/145 (2.07) 8/25 (32) < 0.01
Muscle relaxants n/total (%) 11/148 (7.4) 5/22 (22.7) 0.038
Antimicrobials n/total (%) 83/157 (52.9) 12/20 (60) 0.55
Tacrolimus n/total (%) 26/155 (16.77) 1/17 (5.9) 0.21
Anticonvulsants n/total (%) 17/147(11.6) 1/18 (5.6) 0.39
Antiemetics n/total (%) 54/149 (36.2) 11/20 (55%) 0.10
  1. Abbreviations: CVD cardiovascular disease, HCQ hydroxychloroquine, QTc QT corrected interval, SD standard deviation